A novel anti-galectin-9 immunotherapy limits the early progression of pancreatic neoplastic lesions in transgenic mice

BackgroundPancreatic adenocarcinoma (PDAC) is a devastating disease with an urgent need for therapeutic innovation. Immune checkpoint inhibition has shown promise in a variety of solid tumors, but most clinical trials have failed to demonstrate clinical efficacy in PDAC. This low efficacy is partly...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Alexandre Quilbe, Rami Mustapha, Belinda Duchêne, Abhishek Kumar, Elisabeth Werkmeister, Emmanuelle Leteurtre, Olivier Moralès, Nicolas Jonckheere, Isabelle Van Seuningen, Nadira Delhem
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2023-11-01
Serija:	Frontiers in Immunology
Teme:	pancreatic adenocarcinoma galectin-9 regulatory T cells immunotherapy transgenic mouse model pancreatic intraepithelial neoplasm (PanIN)
Online dostop:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1267279/full
Oznake:	Označite Brez oznak, prvi označite!